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Summary
Insulin resistance is associated with impaired skeletal muscle oxidation capacity and reduced mitochondrial number and
function. Here, we report that adiponectin signaling regulates mitochondrial bioenergetics in skeletal muscle. Individuals
with a family history of type 2 diabetes display skeletal muscle insulin resistance andmitochondrial dysfunction; adiponectin
levels strongly correlate withmtDNA content. Knockout of the adiponectin gene inmice is associated with insulin resistance
and low mitochondrial content and reduced mitochondrial enzyme activity in skeletal muscle. Adiponectin treatment of
human myotubes in primary culture induces mitochondrial biogenesis, palmitate oxidation, and citrate synthase activity,
and reduces the production of reactive oxygen species. The inhibition of adiponectin receptor expression by siRNA, or of
AMPK by a pharmacological agent, blunts adiponectin induction of mitochondrial function. Our findings define a skeletal
muscle pathway by which adiponectin increases mitochondrial number and function and exerts antidiabetic effects.Introduction
As a consequence of the increased prevalence of obesity, type 2
diabetes (T2D) has become a global epidemic, with more than
300 million individuals worldwide projected to be afflicted with
T2D by the year 2025 (Zimmet et al., 2001). Although the primary
cause of T2D is unknown, it is clear that insulin resistance in
skeletal muscle and liver plays a role in its pathogenesis (Lillioja
et al., 1993). Insulin resistance in offspring of parents with type 2
diabetes is a strong predictor of the development of the disease
later in life (Warram et al., 1990). Obese individuals and subjects
with T2D are characterized by reduced adiponectin signaling
(ligand and receptor; Civitarese et al., 2004; Kern et al., 2003;
Rasmussen et al., 2006) and lower rates of fasting lipid utilization
and impaired switch to carbohydrate oxidation in response to
insulin (Kelley et al., 1999; Kelley and Mandarino, 2000). Recent
evidence indicates that insulin resistance in skeletal muscle
maybe be due to reduced mitochondrial oxidative capacity, fat
metabolism (Kelley et al., 2002; Petersen et al., 2004), and
insulin-stimulated ATP production (Petersen et al., 2005).
Bjorntorp and coworkers were among the first to demonstrate
in the 1960s that mitochondria isolated from T2D subjects had
decreased oxidative capacity (Bjorntorp et al., 1967). Recent
studies using microarray expression analyses reported a de-
crease in the expression of genes encoding proteins of mito-
chondrial oxidative phosphorylation in the skeletal muscle of
subjects with insulin resistance (Patti et al., 2003) and T2D (Moo-
tha et al., 2003). Further studies in insulin-resistant individuals
and in subjects with T2D have shown reduced mitochondrial
content (Kelley et al., 2002) and lower electron transport chain
(ETC) activity in total (Kelley et al., 2002; Petersen et al., 2003,
2004), intramyofibular and subsarcolemal mitochondrial frac-
tions (Ritov et al., 2005). Taken together, these data support
the hypothesis that insulin resistance in human muscle arises
from defects in mitochondrial number and function.CELL METABOLISM 4, 75–87, JULY 2006 ª2006 ELSEVIER INC. DOIThe molecular mechanism(s) leading to mitochondrial dys-
function in obesity and T2D remain largely unknown. Bergeron
et al. (2001), demonstrated that activation of 50-AMP-activated
protein kinase (AMPK) increases both mitochondrial biogenesis
and oxidative capacity in skeletal muscle of rodents. Supportive
of the role of AMPK in mitochondrial biogenesis, AMPK-a2 null
mice display reduced PGC1a gene expression (Zong et al.,
2002), a key nuclear transcription coactivator that regulates
genes encoding for mitochondrial function. In animal models
of T2D, the activation of AMPK by adiponectin increasesmuscle
and hepatic fat oxidation and improves insulin sensitivity (Ya-
mauchi et al., 2002). Collectively, these data suggest that ago-
nists of AMPK can increase both the number and the oxidative
capacity of mitochondria, thereby creating a theoretical link be-
tween adiponectin signaling and mitochondrial bioenergetics.
Here, we investigate the relationship between adiponectin and
mitochondrial function in three complementary settings: in mus-
cle from humans who are predisposed to develop T2D; in mus-
cle from insulin-resistant adiponectin KO mice, and in primary
cultures of human myocytes. We define a signaling pathway in
skeletal muscle by which adiponectin (ligand and receptors)
exerts potent antidiabetic effects by inducing AMPKK/AMPK
phosphorylation, increasing mitochondrial number and oxida-
tive metabolism and reducing the generation of reactive oxygen
species (ROS).
Results
Adiponectin pathway is associated with mitochondrial
function in humans
To examine whether adiponectin signaling is associated with
insulin resistance and mitochondrial dysfunction in humans, we
studied young insulin-resistant offspring (n = 8) of parents with
T2D (FH+) and insulin sensitive subjects (n = 10) with no family
history of T2D (FH2) as previously described (Civitarese et al.,10.1016/j.cmet.2006.05.002 75
A R T I C L EFigure 1. Comparison of skeletal muscle mitochon-
drial bioenergetics in insulin-resistant subjects with
at least two first-degree relatives with type 2 diabe-
tes (FH+, -) and insulin-sensitive subjects with no
family history of type 2 diabetes (FH2,,)
A) Mitochondrial content was assessed by mtDNA
copy number.
B) Enzymatic quantification of mitochondrial oxida-
tive capacity in the skeletal muscle of Mexican Amer-
icans revealed reduced citrate synthase (TCA cycle)
and b-hydroxyacyl-CoA dehydrogenase (b-HAD;
b oxidation) activity in FH+ patients.
C) Insulin sensitivity assessed by euglycemic-hyper-
insulinemic clamp (M value, mg glucose $ kg21 $
min21) versus mtDNA copy number levels in skeletal
muscle.
D) mtDNA copy number versus AdipoR1 mRNA
expression in skeletal muscle.
Data represented mean 6 SEM; n = 8, FH+; n = 10,
FH2 subjects.2004). Fasting plasma insulin concentrations were higher in
FH+ versus FH2 subjects (10 6 1 versus 6 6 1 mU/ml, p =
0.02), whereas glucose disposal rate during a hyperinsulinemic-
euglycemic clamp (3.06 0.3 versus 5.66 0.05 mg $ kg21 $ min21,
p = 0.001) and plasma adiponectin concentration (5.4 6 0.41
versus 8.9 6 1.3 mg/ml, p = 0.03) were lower in FH+ versus FH2
subjects (Behre et al., 2006; Civitarese et al., 2004). RNA and
DNA were extracted from a muscle biopsy collected in the
fasting condition to examine by qPCR the expression of 27
candidate genes involved in adiponectin binding, FFA transport
and oxidation, de novo lipogenesis, AMPK signaling, oxidative
transcription, mitochondrial biogenesis, and oxidative stress
(Table S1). The expression level of AMPK-a1 (p = 0.04), PPARg
coactivator-1b (p = 0.04), and mitochondrial transcription factor
A (mtTFA; p = 0.03) were lower in FH+ subjects, suggesting lower
mitochondrial content. Consistent with these results, mitochon-
drial DNA (mtDNA; p = 0.006; Figure 1A), a proxy marker for
mitochondrial content (Wang et al., 1999), citrate synthase
(CS; TCA cycle; p = 0.02), and b-hydroxy-acyl-coenzyme A
dehydrogenase (b-HAD; b oxidation; p = 0.03) enzyme activity
(Figure 1B) were all reduced in FH+ subjects, indicating lowermi-
tochondrial bioenergetic capacity. Analysis of heteroplasmy
revealed no difference between groups, suggesting that mito-
chondrial dysfunction was not due to large mtDNA deletions
(data not shown). In addition, mtDNA content alone accounted
for 55% of the variance in insulin sensitivity (Figure 1C).76We have previously shown that both AdipoR1 and AdipoR2
expression are lower in FH+ versus FH2 subjects and both cor-
relate positively with insulin sensitivity (Civitarese et al., 2004).
Now we show that mtDNA is strongly related to the expression
of both adiponectin receptors (AdipoRs) with the principal corre-
lation with AdipoR1 mRNA (r = 0.77, p < 0.001; Figure 1D). Con-
sistently, mtDNA and AdipoR1 were positively associated with
CS activity (r = 0.71, p = 0.007 and r = 0.58, p = 0.037, respec-
tively; data not shown). In addition, plasma adiponectin concen-
tration correlated positively with insulin sensitivity (M values;
r = 0.52, p = 0.03), mtDNA content (r = 0.59, p = 0.03), b-HAD
(r = 0.71, p = 0.007), and CS activity (r = 0.58, p = 0.037; data
not shown). Collectively, these data reveal that individuals with
a family history for T2D have lower mtDNA copy number and
oxidative capacity and that adiponectin signaling (circulating
plasma adiponectin and AdipoRs expression) is associated
with mitochondrial number and oxidative capacity in human
skeletal muscle.
Adiponectin KO mice display decreased
mitochondrial content
Mice expressing dominant negative AMPK-a2 display reduced
PGC1a mRNA (Zong et al., 2002), whereas transgenic mice
(Combs et al., 2004) and rats (Satoh et al., 2005) overexpressing
adiponectin display improved insulin sensitivity and increased
markers of mitochondrial function in adipose tissue (CombsCELL METABOLISM : JULY 2006
Adiponectin and skeletal muscle bioenergeticsFigure 2. Molecular characterization of 12-week-old
wt and adiponectin KO mice
A) Gastrocnemius (Gastroc) and Soleus muscle from
mice was used in qPCR analysis of mtDNA copy
number and mitochondrial enzyme activity. Analysis
of mtDNA copy number (A), cytochrome c oxidase
(B), and citrate synthase enzyme activity (C) in KO
mice revealed reduced mitochondrial bioenergetics.
Data represented mean6 SEM; wt, n = 5; KO, n = 5.
*p < 0.05 compared to wt mice. Protein content of
myosin chain 1 and troponin-1 (slow) in gastrocne-
mius muscle (D). Immunoblotting was undertaken
in six mice (wt, n = 3; KO, n = 3) and data are shown
as a representative blot.et al., 2004). To investigate the relationship between adiponectin
and mitochondria, we examined mitochondrial function in the
muscle of adiponectin null mice. Thiazolidinediones (TZD) are
effective insulin sensitizers in part by inducing the transcription
of genes involved in preadipocyte differentiation (Gurnell et al.,
2000) and increasing the production of circulating adiponectin
(Maeda et al., 2002). To maximize differences in the concentra-
tion of adiponectin, male wt and adiponectin KO mice were
maintained on a high-fat diet for 8 weeks in conjunction with ro-
siglitazone treatment at adoseof 10mg/kg/dayduring the last 10
days before sacrifice. This treatment was reported to increase
circulating adiponectin byw4-fold in wild-type mice (Nawrocki
et al., 2006). Both groups (wt and KO) had comparable body
weights after TZD treatment but adiponectin deficient mice
were glucose intolerant as evidenced by an oral glucose toler-
ance tests (2.5 mg glucose/g body weight; Nawrocki et al.,
2006). These data are consistent with previous reports of insulin
resistance in adiponectin null mice (Kubota et al., 2002; Maeda
et al., 2002). Consistent with our hypothesis, transcription of mi-
tochondrial markers (PGC1a andPGC1b) and of the fat oxidative
transcription factor PPARawas reduced in the gastrocnemius of
adiponectin KO mice compared to wt mice (data not shown).
MtDNA content (4103 6 188 versus 5261 6 509 mtDNA copy
number, p < 0.05), and CS activity (49 6 7 versus 74 6 10
mmol/min/mg protein, p < 0.05), were lower in KO mice relative
to wt mice, whereas COX activity was not (23 6 5 versus 35 6
6 mmol/min/mg protein, p = 0.12). To exclude the potential con-
founding effects of TZD treatment (Bogacka et al., 2005), we also
examined mitochondrial number and function in 12-week-old
female mice. MtDNA content was reduced byw22% in the gas-CELL METABOLISM : JULY 2006trocnemius muscle (mixed fiber type) of KO mice relative to wt
mice (Figure 2A; p = 0.058) and byw37% in the oxidative soleus
muscle (Figure 2A; p = 0.025). PGC1a mRNA was lower in both
fiber types in KO animals, whereas PGC1b was only different
between fiber types and not genotype (Table 1). The data is con-
sistent with previous reports in C57/BL6 mice showing elevated
PGC1amRNA in oxidativemuscle (Lin et al., 2002). Furthermore,
Table 1. Expression of genes involved in mitochondrial biogenesis, fiber type
determination, and fat oxidation in 12-week-old wt and adiponectin-deficient mice
Gene Muscle
Wild-Type Adiponectin KO
mRNA/ RPLPO mRNA (Arbitrary Units)
PGC1a Soleus 348 6 13 201 6 32a
Gastrocnemius 224 6 20b 158 6 11a,b
PGC1b Soleus 4.3 6 0.4 3.4 6 0.9
Gastrocnemius 2.9 6 0.7b 3.6 6 0.5
NRF-1 Soleus 18 6 1 18 6 2
Gastrocnemius 23 6 2 16 6 0.6
PPARd Soleus 113 6 4 85 6 7a
Gastrocnemius 124 6 11 98 6 6a
PPARa Soleus 94 6 10 79 6 12
Gastrocnemius 32 6 12b 27 6 6b
UCP3 Soleus 65 6 21 69 6 19
Gastrocnemius 85 6 18 129 6 48
PGC1a, peroxisome proliferative activated receptor gamma coactivator-1 alpha;
PGC1b, peroxisome proliferative activated receptor gamma coactivator-1 beta;
NRF1, nuclear respiratory factor 1; PPARd, peroxisome proliferative activated
receptor-delta; PPARa, peroxisome proliferative activated receptor-alpha; and
UCP3, uncoupling protein 3. Data represented mean 6 SEM, n = 5 each group.
a p < 0.05 compared to wt mice.
b p < 0.05 compared to soleus.77
A R T I C L ECOX activity was reduced in both the gastrocnemius and soleus
muscle (Figure 2B), whereas, CS activity was reduced in soleus
muscle only (Figure 2C). Collectively, these data indicate thatmi-
tochondrial content and oxidative capacity are dependent on the
presence of circulating adiponectin.
Skeletal muscle contains both oxidative (type 1) and glycolytic
(types 2a and 2b) myofibers that differ in oxidative capacity
mostly due to the synthesis of a distinct array of contracting pro-
teins (i.e., troponin-1 slow), enzymes, and regulatory proteins
(Berchtold et al., 2000). The fact that PGC1a is a master regula-
tor of mitochondrial biogenesis prompted us to study the poten-
tial role of adiponectin in the regulation of proteins involved in
fiber type determination in wt and adiponectin KO mice. In gas-
trocnemius (a muscle with a mixture of type 1 and type 2 fibers),
the expression of markers of type 1 fibers such as troponin-1
(Polly et al., 2003) and slowmyosin (Semper et al., 1988) was re-
duced in adiponectin KO mice compared to wt mice (Figure 2D)
suggesting lower content of oxidative fibers. Interestingly, in
primary human muscle cell culture (see below) globular adipo-
nectin (gAD) dose-dependently induced troponin-1 mRNA (see
Figure S2A in the Supplemental Data available with this article
online), suggesting the reduction in troponin-1 protein in KO
mice is regulated at the transcriptional level. In addition, KO
mice also had reduced PPARd mRNA (Table 1), which has
been shown to induce fiber type switching in skeletal muscle
(Wang et al., 2004). Taken together, the reduced protein expres-
sion of troponin-1 and slow myosin reemphasizes the role of
adiponectin in muscle bioenergetics.
Adiponectin treatment increases mitochondrial
bioenergetics in primary human myotubes
Adiponectin exists in human plasma as full-length protein aswell
as smaller globular fragments (Fruebis et al., 2001). gAD binds
more avidly than full-length adiponectin to C2C12 myocytes,
skeletal muscle membranes (Yamauchi et al., 2002, 2003), and
mouse macrophages (Yamaguchi et al., 2005). To determine
whether the adiponectin pathway was involved in the regulation
of mitochondrial content, we treated primary human myotubes
taken from the vastus lateralis muscle of five healthy male Cau-
casian subjects (see Experimental Procedures for clinical char-
acteristics) with gAD. Two day treatment with 0.25 and 0.5 mg/ml
of gAD increased mtDNA content, indicating an induction in
mitochondrial biogenesis (Figure 3A). To rule out the possibility
that the observed increases were due to increased mtDNA sta-
bility rather than to changes in true mitochondrial number, we
directly measured mitochondrial mass using MitoTracker Green
(Wilson-Fritch et al., 2004). gAD treatment increased mitochon-
drial content (Figures 3B and 3C) in parallel with increased
PGC1amRNA (Figure S1A). Consistently, citrate synthase activ-
ity, a biomarker of mitochondrial function (Figure 5B) and CO2
production from palmitate oxidation (Figure 3D) was increased
with gAD treatment. These data demonstrate that adiponectin
can augment both mitochondrial mass and oxidative capacity.
In addition, gAD dose-dependently increased AMPK phosphor-
ylation (Tomas et al., 2002) and PGCla protein (Figure 3E).
Adiponectin forms a wide range of multimers, from LMW tri-
mer to HMW multimers in human serum (Fruebis et al., 2001;
Pajvani et al., 2003). We compared the potencies of various
forms of adiponectin in myotubes treated with adiponectin.
Cys39Ser mutant LMW adiponectin (Pajvani et al., 2003;
Figure S1B), but not HMW adiponectin, stimulated mitochon-78drial biogenesis (data not shown), indicating differing bioactivity
of the two isoforms in skeletal muscle. Because leptin has also
been shown to stimulate AMPK in skeletal muscle (Minokoshi
et al., 2002), activation of AMPK and mitochondrial biogenesis
may be a common mechanism by which insulin-sensitizing adi-
pokines such as adiponectin and leptin increase insulin sensitiv-
ity. Consistent with this hypothesis, leptin treatment of primary
human myotubes for 72 hr increased mitochondrial DNA con-
tent relative to control (Figure S1C).
Adiponectin treatment reduces the generation
of reactive oxygen species
Cellular respiration strips electrons from fatty acids (FA), carbo-
hydrates, and amino acids, and the electrons subsequently ac-
cumulate on the soluble electron carriers NADH and FADH2. The
electrons are passed down the respiratory chain to oxygen, cre-
ating a potential energy gradient of protons (DmH+), increased
membrane potential (Dc) and a pH gradient (DpH; Luvisetto
et al., 1990) to drive ATP synthesis. IncreasedDc is also a central
bioenergetic factor that regulates the generation of reactive ox-
ygen species (ROS); super oxide radical (O2
2), hydrogen per-
oxide (H2O2), and the hydroxyl radical (OH
; Maassen et al.,
2002; Nicholls, 2004). In human myotubes, gAD reduced the
fluorescence signals for hydrogen peroxide (Figure 4A) and
superoxide production (Figures 4E and S2A). ROS production
is inversely related to mitochondrial content per cell (Maassen
et al., 2002). Each mitochondrion exhibits an increased work-
load when mitochondrial mass is reduced, and this leads to
higher Dc and increased ROS production. Analysis of Dc using
tetramethylrhodamine ethyl ester (TMRE) in cells treated with
0.25 mg/ml of gAD indicated a reduction in Dc (Figure 4B).
UCP3 overexpression in L6 myotubes reduces the generation
of hydrogen peroxides (MacLellan et al., 2005). Analysis of
UCP3 mRNA in cells treated with 0.5 mg/ml of gAD demon-
strated no difference in UCP3 expression (8.6 6 0.9 versus
10.2 6 0.8, control versus 0.5 mg gAD, respectively; p = 0.13).
These data suggest decreased ROS production with gAD treat-
ment is mediated in part, by a lowering of mitochondrial Dc.
Mitochondria are normally protected against the effects of
ROS by a complex system of antioxidants and scavenging
enzymes including heme oxygenase (HO1), NAD(P)H dehydro-
genase-quinone-1 (NQO1), 8-oxoguanine DNA glycosylase
(OGG1), superoxide dismutase 2 (SOD2) and glutathione per-
oxidase-1 (GPx1). gAD treatment for 48 hr reduced HO1, NQO1,
and OGG1 mRNA (Figures S2B–S2D), which is consistent with
ROS regulating the transcription of these genes (Boiteux and
Radicella, 2000; Elbekai and El-Kadi, 2005; Friesen et al., 2004;
Gong et al., 2004; Guo et al., 2003). In addition, SOD2 mRNA
was increased relative to controls (Figure 4C), suggesting that
adiponectin can induce SOD2 activity. To clarify the mecha-
nisms by which adiponectin reduce ROS, we measured total
SOD and GPx activity in primary muscle cells treated with 0.25
mg/ml of gAD. gAD increased the activity of SOD (Figure 4D),
which is consistent with the reduction in the fluorescence of Mi-
toSOX Red. SOD catalyses the dismutation of superoxide radi-
cals to hydrogen peroxide and oxygen (Luo et al., 2006). We
found no change in GPx activity (data not shown), suggesting
the reduction in hydrogen peroxide observed with adiponectin
treatment (Figure 4A) maybe the result of lower superoxide gen-
eration. Importantly, AdipoR-specific small-interfering (si) RNA
to both receptors abolished the induction in SOD activityCELL METABOLISM : JULY 2006
Adiponectin and skeletal muscle bioenergeticsFigure 3. Effects of adiponectin treatment on mito-
chondrial number and oxidative capacity in primary
human myotubes
A and B) Primary human myotubes were treated for
48 hr with 0.1, 0.25, and 0.5 mg/ml of gAD and mito-
chondrial content measured using mtDNA copy
number (A) and MitoTracker Green (B).
C) Myotubes were treated with 0.25mg/ml gAD for 48
hr and cells subsequently incubated with 100 nM
MitoTracker Green FM for 30 min. Mitochondrial mass
is indicated by green fluorescence. Images were ac-
quired within 5 min using a conventional wide-field
microscope fitted with an 340 Nikon plan-apo
objective.
D) Effects of gAD treatment on fatty acid oxidation.
Data represented as mean 6 SEM; n = 5. *p < 0.05
compared to control.
E) Dose-dependent induction in AMPK-P and total
PGC1a protein by 0.1, 0.25, and 0.5 mg/ml of gAD.(Figure 4D), indicating the increase in SOD activity was specific
to adiponectin signaling. Treatment of cultured human endothe-
lial cells with 5-amino oimidazole-4-carboxamide ribonucleo-
side (AICAR), an AMPK activator (Kaushik et al., 2001) induced
SOD2 mRNA and lowered the production ROS (Kukidome
et al., 2006). In this study, treatment of primary muscle culture
with 0.5mMAICAR restoredSODactivity to levels similar to those
observed with gAD treatment (Figure 4D). Collectively, these
data show that adiponectin lowers the production of ROS by
both reducingmitochondrial membrane potential and increasing
ROS scavenging vis-a`-vis AMPK-SOD2.
Reduction of AdipoR reduces adiponectin-induced
mitochondrial oxidative capacity
We examined the effects of AdipoR-specific siRNA on adipo-
nectin-induced mitochondrial biogenesis in primary humanCELL METABOLISM : JULY 2006myotubes. Knockdown of AdipoR1, AdipoR2, or the combina-
tion of both receptors significantly reduced gAD induction of
mtDNA (data not shown), mitochondrial mass (Figure 5A), CS
activity (Figure 5B), and CO2 production (Figure 3D). These
data suggest that both AdipoRs contribute to the regulation of
mitochondrial mass and function in human skeletal muscle.
Similar reductions in mtDNA were observed using AdipoR1-
siRNA and coincubation with the Cys39Ser mutant LMW-adipo-
nectin (Figure S1D).
Activation of AMPK in rodents (Bergeron et al., 2001) induces
mitochondrial biogenesis and increases mitochondrial oxidative
output.We testedwhether inhibiting AMPK activity would impair
adiponectin-induced activation of mitochondrial function.
Adenine-9-b-D-arabinofuranoside hydrate (ara-A), an AMP
analog and competitive AMPK inhibitor (Musi et al., 2001), de-
creased gAD-stimulated AMPK phosphorylation (see below),79
A R T I C L EFigure 4. Effects of adiponectin treatment on mito-
chondrial ROS production in primary human myo-
tubes
To analyze ROS levels in myotubes, cells were incu-
bated with DCFDA (A) (indicator of hydrogen per-
oxide) and (B) Tetramethylrhodamine ethyl ester
(TMRE) for estimation of membrane potential.
C) mRNA expression of SOD2 in myotubes treated
with 0.1, 0.25, and 0.5 mg/ml of gAD for 48 hr.
D) Total SOD activity (Cu/Zn-, Mn-, and Fe-SOD) in
cells treated with 0.25 mg/ ml of gAD, mock-siRNA,
AdipoR1/R2-specific siRNA, and AICAR. Data repre-
sented asmean6 SEM; n = 5. *p < 0.05 compared to
control.
E) The presence of ROS in myotubes treated with
0.25 mg/ml of gAD for 48 hr. Red fluorescence indi-
cates the presence of ROS.mitochondrial biogenesis, and CS activity (Figures 5A and 5B),
indicating that signaling through AMPK is a necessary postadi-
ponectin receptor event.
Adiponectin-mediated signaling
AMPK is allosterically activated by alterations in the AMP:ATP
ratio and covalently by phosphorylation at Thr172 by upstream
kinase AMPK kinase (Hawley et al., 2003; Woods et al., 2003).
gAD treatment of myotubes for 48 hr increased the phosphory-
lation of AMPKK, AMPK (Chen et al., 2005; Yamauchi et al.,
2002), and total PGC1a and COX protein content (Figure 5C).
Consistently, recent work demonstrated that overexpression
of PGC1a in L6 myocytes also induces COX protein (Koves
et al., 2005). Suppression of AdipoR1, AdipoR2, or the combina-
tion of both receptors was associated with reduced AMPKK and
AMPK phosphorylation (Fujioka et al., 2006) and lower PGC1a
and COX protein content. AdipoR1-specific siRNA caused80a greater reduction in AMPK phosphorylation and PGC1a pro-
tein relative to AdipoR2-siRNA. However, knockdown of both
AdipoRs yielded an additive effect (Figure 5C). Collectively,
these data provide evidence that AdipoR can mediate the
gAD-stimulated induction in AMPK phosphorylation and
PGC1a protein in human skeletal muscle.
In vitro, the binding of AMP to AMPK enhances w3-fold the
rate at which AMPK can be phosphorylated and activated by
AMPKK-STRAD-MO25 complex (Hawley et al., 2003; Woods
et al., 2003). Consistent with these observations, ara-A treat-
ment decreased the phosphorylation of AMPKK and AMPK
and PGC1a and COX protein content (Figure 5C). This data
are in accord with mice overexpressing dominant-negative
AMPK-a2, which have reduced PGC1a mRNA and mitochon-
drial content (Zong et al., 2002). Thus, stimulation of mitochon-
drial biogenesis by gAD occurs through the activation of
AMPKK-AMPK in primary human myotubes.CELL METABOLISM : JULY 2006
Adiponectin and skeletal muscle bioenergeticsFigure 5. Effects of suppression of AdipoR1 or Adi-
poR2 expression by siRNA and pharmacological
inhibition of AMPK activity using ara-A in primary
human myotubes
A and B) mitochondrial content (A) and citrate syn-
thase activity (B) in myotubes treated with siRNA
duplex and ara-A compound. Data represented
mean 6 SEM; n = 5. *p < 0.05 compared to control.
#p < 0.05 compared to mock-siRNA.
C) Phosphorylation and total amount of AMP-acti-
vated protein kinase kinase (AMPKK) (a and b),
AMP-activated protein kinase (AMPK) (c and d),
and total amount of peroxisome proliferative acti-
vated receptor g coactivator 1-a (PGC1a) (e), cyto-
chrome c oxidase (f), cAMP response element bind-
ing protein (CREB) (g), Myocyte enhancer factor 2C
(MEF2C) (h), and b-actin protein (i) in primary human
myotubes transfected with siRNA duplex or ara-A
and incubated with 0.25 mg/ml gAD for 48 hr in dupli-
cate cell incubations.Myocyte enhancer factor 2C (MEF2C) and cAMP response el-
ement binding protein (CREB; Handschin et al., 2003) bind to the
PGC1a promoter increasing PGC1 content, promoting mito-
chondrial biogenesis and increasing oxidative fiber types.
MEF2C activity is regulated in part through AMPK signaling
(Al-Khalili et al., 2004), while both CREB and MEF2C are acti-
vated by calcium signaling kinase calcium/ calmodulin-depen-
dent protein kinase (CaMKIV) and calcineurin A (can; Corcoran
and Means, 2001; Handschin et al., 2003). gAD increased
MEF2C protein content without a change in CREB protein (Fig-
ure 5C). Conversely AdipoR-specific siRNA or chemical inacti-
vation of AMPK with ara-A completely blocked the induction
of MEF2C protein but had no effect on CREB protein. Collec-
tively, these data suggest that the activation of mitochondrial
biogenesis by gAD occurs through the induction of AMPK,
MEF2C, and PGC1a.
Discussion
Adiponectin signaling is an important regulator of skeletal mus-
cle mitochondrial oxidative capacity based on the followingCELL METABOLISM : JULY 2006findings: (1) In FH+ subjects, insulin resistance and mitochon-
drial dysfunction in skeletal muscle were associated with lower
levels of circulating adiponectin and AdipoR mRNA expression;
(2) in vivo, plasma adiponectin and AdipoR1mRNA is a correlate
of mtDNA; (3) in vitro, adiponectin induced mitochondrial bio-
genesis and oxidative output and reduced the production of
ROS; (4) the induction of mitochondrial biogenesis and in-
creased oxidative capacity by gAD was inhibited by targeted
suppression of the AdipoRs; (5) adiponectin KO mice have re-
duced mitochondrial content, TCA cycle, and ETC activity and
reduced markers of type-1 oxidative fibers in skeletal muscle.
Collectively, these data define a pathway in skeletal muscle by
which adiponectin signaling contributes to energy homeostasis
by modulating mitochondrial number and function.
It has become increasingly clear that lower mitochondrial
number (Kelley et al., 2002; Ritov et al., 2005) and oxidative ca-
pacity (Bjorntorp et al., 1967; Kelley et al., 2002; Petersen et al.,
2003; Ritov et al., 2005) are central defects in the development
of insulin resistance in skeletal muscle. Results from the current
study and Petersen et al. (2004) demonstrate that mitochondrial
dysfunction is present in the prediabetic state, suggesting that81
A R T I C L Emitochondrial abnormalities may be primary to the development
of T2D. The functional consequence of deficient b-oxidation and
impaired ETC activity might be the accumulation of intramyocel-
lular lipids (acylcarnitines, fatty acyl CoAs, diacylglycerols, and
ceramides) that can activate serine kinases that inhibit insulin
signaling and glucose transport (Adams et al., 2004; Chavez
and Summers, 2003; Yu et al., 2002). Elegant work by Ritov
et al. (2005), showed the ETC activity of subsarcolemmal mito-
chondria are reduced in subjects with T2D. This latter observa-
tion is important, ‘‘since subsarcolemmal mitochondria provide
energy for membrane-related processes, including signal trans-
duction, ion exchange, and substrate transport—processes
involved in insulin action, glucose uptake, and storage’’ (Ritov
et al., 2005). The key question is what is the physiological impor-
tance of adiponectin signaling in the regulation of mitochondrial
bioenergetics?
Studies in obese and diabetic rhesus monkey demonstrate
that plasma adiponectin level declines in the early phases of
obesity and in parallel to the progressive development of insulin
resistance (Hotta et al., 2001). Furthermore, circulating plasma
adiponectin levels and the expression of both AdipoRs are re-
duced in subjects with a family history of T2D (Civitarese et al.,
2004), while prospective studies in Pima Indians demonstrate
that high concentrations of adiponectin is protective against
the development of T2D (Lindsay et al., 2002). Collectively,
these data suggest that early defects in the secretion of adipo-
nectin or adiponectin signaling may be a contributing factor to
lower mitochondrial content and/or function in the prediabetic
state. However, not all studies report lower adiponectin concen-
trations in FH+ subjects (Kriketos et al., 2004; Petersen et al.,
2004; Tschritter et al., 2003). Potential confounding factors
may include classification of FH status (i.e., one or both parents
with type 2 diabetes in FH+ groups) (Behre et al., 2006), gender
(Kern et al., 2003), and adiposity (Behre et al., 2006; Kern et al.,
2003).
In our study, adiponectin treatment induced mitochondrial
oxidative capacity and increased PGC1a protein in human
myotubes. Recent work in both animal and cell culture models
demonstrate the inability of mitochondria to oxidize lipid in re-
sponse to fatty acid exposure (fasting and a high-fat diet) is de-
pendent on PGC1amRNA expression (Koves et al., 2005). Con-
versely, overexpression of PGC1a in L6myocytes resulted in the
complete oxidation of lipid and the elevated transcription of
PGC1a target genes (b-oxidation and TCA cycle; Koves et al.,
2005). Taken together, these data imply that the ability of skele-
tal muscle to effectively switch from glucose to fatty acid oxida-
tion during increased fatty acid supply (metabolic adaptability)
relies upon on mitochondrial content and the expression level
of PGC1a, both of which are targets of the adiponectin signaling
pathway (Figure 6).
Overexpression of PGC1a in muscle results in a dramatic in-
crease in insulin sensitive type 1 oxidative fibers (Lin et al.,
2002). The increase in PGC1a activity occurs mainly through
calcium signaling and activation of PGC1a promoter by CREB
and MEF2 binding sites (Wu et al., 2002). In the present study,
gAD treatment increased PGC1a and MEF2C protein expres-
sion in parallel to increased transcription in troponin-1. MEF2C
directly binds and activates transcription of troponin-1 in
C2C12 myotubes (Polly et al., 2003) and transgenic overexpres-
sion of PGC1a increase troponin-1 protein in oxidative fibers (Lin
et al., 2002). Importantly, analysis of the gastrocnemius muscle82from adiponectin KO mice revealed lower PGC1a mRNA and
mitochondrial content, reduced tropinin-1 protein expression.
These data suggest that circulating adiponectin contributes
to protein expression of genes involved in myofiber determina-
tion by a signaling mechanism involving PGC1a, MEF2C, and
troponin-1.
We have also shown the induction of mitochondrial function
by gAD occurs in parallel with increased AMPKK phosphoryla-
tion. Recent data in primary human myotubes demonstrate
that AMPKK is not activated in response to acute gAD treatment
(<6 hr), despite significant increases in AMPK Thr172 phosphor-
ylation (Chen et al., 2005), suggesting that longer exposure
(48 hr) to gAD is required to induce AMPKK activity and mito-
chondrial biogenesis. Chen et al. (2005) found impaired gAD in-
duction of AMPK activity in primary myotubes from obese T2D
subjects that was not associated with changes in the gene ex-
pression of the adiponectin receptors. This does not exclude
Figure 6. Adiponectin signaling and the regulation of mitochondrial function in
skeletal muscle
Adiponectin binding to its AdipoRs activates AMP-activated protein kinase
(AMPK) and stimulates the phosphorylation of ACC2 and fatty-acid oxidation (Ya-
mauchi et al., 2002, 2003). Adiponectin also activates peroxisome proliferative
activated receptor-a (PPARa) stimulating transcription of genes in the fatty-acid
oxidation pathway and decreasing triglyceride content in muscle (Yamauchi
et al., 2001, 2002) and improving insulin sensitivity. Independent of changes in
transcription and mitochondrial mass, the improvements in lipid oxidation occur
in less than 6 hr (Yamauchi et al., 2002). Adiponectin activation of AMPK by up-
stream kinase AMPK kinase (AMPKK) activates transcription of myocyte enhancer
factor 2C (MEF2C) and phosphorylation of peroxisome proliferative activated
receptor g coactivator 1-a (PGC1a), which in turn increasesmitochondrial content,
oxidative capacity, and oxidative-fiber type composition. Central to the develop-
ment of mitochondrial dysfunction is reactive oxygen species (ROS) production,
which reacts with DNA, protein, and lipids leading to oxidative damage. ROS pro-
duction is inversely related to mitochondrial content. Activation of the adiponectin
pathway reduces the generation of ROS by two processes: (1) Increased mito-
chondrial content, which in turn decreases the workload for each mitochondrion
leading to reduced membrane potential (YDc) and lower ROS production; and
(2) adiponectin increases PGC1a activity which increases the transcription/activ-
ity of the antioxidant enzyme SOD2 that decreases super oxide radical (O2
2)
(Maassen et al., 2002).CELL METABOLISM : JULY 2006
Adiponectin and skeletal muscle bioenergeticsthe possibility that the expression of both AdipoRs may be reg-
ulated by factors that are altered within the hormonal milieu of
obese and obese type 2 diabetic subjects. In support of this,
we (A.E.C. and B.U., unpublished data) and others (Fang
et al., 2005; Tsuchida et al., 2004) have found that AdipoR1
mRNA is lowered by high concentrations of insulin (100–200
nM) and palmitate (60–150 mM; A.E.C. and B.U., unpublished
data) in muscle cell cultures. Intriguingly, we observe no differ-
ence in the expression of AdipoRs in the muscle of adiponectin
KO mice relative to wt mice (A.E.C. and A.R. Nawrocki, unpub-
lished data) or in primary muscle cell culture after treatment with
globular or full-length adiponectin (A.E.C. and B.U., unpublished
data), consistent with data in transgenic rats overexpressing
adiponectin with no difference in the skeletal muscle expression
of both AdipoRs (Satoh et al., 2005). Taken together, these data
do not support the common feedback regulation of hormone-
ligand receptor interaction of which leptin is an example. Not
all G-coupled receptors undergo immediate downregulation in
response to receptor agonist. Classical work examining the reg-
ulation of the b2-adrenergic receptor demonstrates that in the
short-term, agonist-induced changes in receptor binding prop-
erties can account for much of the decrease in receptor-medi-
ated signaling and is unrelated to any physical translocation or
degradation of the receptor molecule (Hausdorff et al., 1991;
Mahan et al., 1985;Wang et al., 1989). This suggests that recep-
tors for adiponectin may also exhibit similar properties. Clearly,
further studies are required investigating the regulation of the
AdipoRs in skeletal muscle.
We show that adiponectin increases mitochondrial content,
SOD2 activity and reduces the fluorescence of TMRE (YDc)
resulting in lower ROS production as measured by DCFDA
(Kukidome et al., 2006; MacLellan et al., 2005). This effect is im-
portant as mitochondria from subjects with T2D have damaged
inner-membrane structure (Kelley et al., 2002) as well as re-
duced electron transport chain activity (Petersen et al., 2004;
Ritov et al., 2005). The inner mitochondrial membrane (cristae)
are particularly prone to oxidative stress as a large portion of
protein complexes associated with oxidative phosphorylation
are embedded in this area (Gilkerson et al., 2003). In addition,
in primary muscle cell culture, gAD and AICAR increased the
activity of SOD. This is in agreement with Kukidome et al.
(2006), who demonstrated that AICAR and overexpression of
PGC1a increases SOD2 mRNA and lower ROS production.
This suggests that under normal physiological conditions,
AMPK and PGC1a activation by adiponectin (or other stimuli)
may be a normal physiological response to reduce the produc-
tion of ROS. We speculate that lower circulating adiponectin
and/or receptor expression contributes to lower mitochondrial
content, decreased SOD2 activity, and increased mitochondrial
oxidative damage.
The lowering of mitochondrial Dcwith gAD treatment was un-
expected and did not relate to any changes in UCP3 mRNA. It is
unclear whether mitochondrial proliferation can reduce ROS
production. Old mitochondria produce less ATP and have
increased ROS production (Miyoshi et al., 2006). In addition,
under well-coupled conditions, phosphorylating mitochondria
have slightly lower Dc and generate less ROS (Nicholls, 2004).
It is possible that newly formed mitochondria have ‘‘more
efficient’’ coupling and ATP production. Further, studies are re-
quired to clarify the link between adiponectin, mitochondrial
biogenesis, Dc, and ROS regulation.CELL METABOLISM : JULY 2006In summary, our results demonstrate that adiponectin and the
AdipoRs play an important role in the regulation of mitochondrial
number and function. Subjects with T2D have reduced adipo-
nectin and decreased adiponectin receptor expression prior to
the onset of hyperglycemia. Activation of the adiponectin path-
way is a promising target for the treatment of insulin resistance
and other components of the metabolic syndrome.
Experimental procedures
Human subjects
Subject recruitment was conducted in the General Clinical Research Center
of the South Texas Veterans Health Care System, Audie Murphy Division, in
San Antonio as previously described (Civitarese et al., 2004). The Institutional
Review Board of the University of Texas Health Science Center at San
Antonio approved the research, and all subjects gave written informed
consent.
Generation of adiponectin KO mice
Adiponectin KO mice were generated as previously described (Nawrocki
et al., 2006). Briefly, a mouse 129/SvEv genomic library was screened and
a positive adiponectin clone was isolated and inserted into a targeting vector
containing a 2.74 kb BamHI fragment and a 4.3 kb SalI to ClaI fragment into
a neomycin cassette (Stratagene). The correct clone was isolated by screen-
ing 750 clones by transforming ES cells in the presence of G418 and analyzed
by Southern blotting. The targeted ES cells were injected into C57BL/6J blas-
tocysts and transferred into foster females. Germline transmission was
obtained from seven chimeric males, with no phenotypic differences were
observed between the lines.
Immunoblotting and mRNA analysis
Immunoblotting for protein and mRNA analysis using qRT-PCR were per-
formed as previously described (Heilbronn et al., 2005). Gene-specific primer
and probe sets are provided in Table S2.
Skeletal muscle cell culture
Vastus lateralis muscle biopsy (w100 mg) were obtained from five healthy
young sedentary subjects (BMI = 24.16 0.5; body fat = 156 1%; fasting glu-
cose concentration = 886 2 mg/dl; fasting plasma insulin = 4.46 0.9 mU/ml)
using the Bergstrom technique (Bergstrom, 1975). Satellite cells were iso-
lated as previously described (Ukropcova et al., 2005). Cells were seeded
into 12- (RNA/DNA) and 6-well plates (protein) at a density of 20 3 103 cells
per cm2 and grown at 37ºC in a humidified atmosphere of 5% CO2. In se-
lected cells, two pairs of Stealth-siRNAs were chemically synthesized (Invi-
trogen), annealed, and transfected (200 pmol/ml) into 50%–70% confluent
primary human myocytes using GeneSilencer siRNA transfection reagents
(Gene Therapy Systems). The sequences of the sense siRNA are as follows:
AdipoR1, AAACAGCACGAAACCAAGCAGAUGG; AdipoR2, AUGUCCCA
CUGGGAGAC UAUAAUGG. Cells transfected with nonfunctional-jumbled
siRNA (Mock) (Ambion) were used as negative controls. Differentiation of
myoblasts into myotubes was initiated as previously described (Ukropcova
et al., 2005). Seventy-two hours after the induction of differentiation, the me-
dium was changed and treated with globular (R&D Systems) or LMW/HMW
adiponectin for 48 hr.
Mitochondrial content and enzyme activity assay
For quantification of mitochondrial content, we used mtDNA as previously
described (Heilbronn et al., 2005) and MitoTracker Green probe (Molecular
Probes). Specific human and mouse primer and probe sets are provided in
Table S2. MitoTracker Green probe preferentially accumulates in mitochon-
dria regardless of the mitochondrial membrane potential and provides an ac-
curate assessment of mitochondrial mass. Cells were washed with PBS and
incubated at 37ºC for 30 min with 100 nM MitoTracker Green FM (Molecular
Probes). Cells were harvested using trypsin/EDTA and resuspended in PBS.
Fluorescence intensity was detected with excitation and emission wave-
lengths of 490 and 516 nm, respectively, and values corrected for total pro-
tein (mg/ml). Mitochondrial heteroplasmy were undertaken as described
previously (Heilbronn et al., 2005). Citrate synthase, cytochrome c oxidase,83
A R T I C L Eand b-HAD activities were determined spectrophotometrically from cell
homogenates using previously described methods (Heilbronn et al., 2005).
Antioxidant enzyme activity
Cell lysates were prepared by sonication in cold 20 mM HEPES buffer (pH
7.2), containing 1 mM EDTA, 210 mM mannitol, and 70 mM sucrose and
centrifuged at 1500 3 g for 5 min at 4ºC for SOD samples and in cold 5
mM Tris-HCL (pH 7.5), containing 5 mM EDTA and 1 mM DTT and centri-
fuged at 10,000 3 g for 15 min at 4ºC for GPx samples. Total SOD activity
(Cu/Zn-, Mn-, and Fe-SOD) was measured by measuring the dismutation
of superoxide radicals generated by xanthine oxidase and hypoxanthine.
GPx activity was measured by the GPx1-mediated oxidation of glutathione
with the recycled reduction of GSSG to GSH by glutathione reductase using
NADPH as a reductant. Both enzyme activities were determined by an indi-
rect assay according to the commercially available CaymanChemicals assay
kits.
Mitochondrial measurements of ROS production
and mitochondrial membrane potential
Hydrogen peroxide
Myotubes were incubated in PBS containing 1 mmol/l of the H2O2-sensitive
fluorescent probe 1 carboxy-H2 [5-(and-6)-carboxy-2
0, 70-dichlorohydofluor-
escein diacetate] (DCFDA; Molecular Probes) for 15min in the dark at 37ºC in
5%CO2. Myotubes were washed twice with PBS and fluorescence emission
measured at 490 nm and 516 nm, respectively.
Superoxide
Superoxide production was measured in myotubes grown in 96-well opaque
plates and stained using MitoSOX red. Briefly, cells were incubated in Hanks
balanced salt solution (HBSS) containing 2 mM of MitoSOX red for 10 min in
the dark at 37ºC in 5% CO2. Cells were washed three times in warm HBSS
and fluorescence intensity detected with excitation and emission wave-
lengths of 510 and 580 nm, respectively. Fluorescent values for both the
DCFDA and MitoSOX assay were corrected for cell density using mg of
protein.
Membrane potential
Tetramethylrhodamine ethyl ester (TMRE; Molecular Probes) is a cationic, li-
pophilic dye that accumulates in the negatively chargedmitochondrial matrix
according to the Nernst equation potential. For estimation of membrane po-
tential, cells were incubated with differentiation media containing 100 nM
TMRE for 20 min at 37ºC in a humidified atmosphere of 5% CO2. At the
end of 20 min, cells were washed three times with PBS, and a micro plate
reader was used to measure TMRE fluorescence (excitation 549 nm, emis-
sion 574 nm). Fluorescent values were corrected for mtDNA copy number
as a marker of mitochondrial mass.
Determination of fatty acid metabolism
Myocytes maintained in differentiation medium for 5 days with either gAD
(0.25 and 0.5 mg/ml), mock-siRNA, AdipoR1/R2-specific siRNA, or ara-A
were incubated at 37ºC in sealed 24-well plates containing 1000 ml serum-
free DFM plus 12.5 mmol/l HEPES, 0.2% BSA, 1.0 mmol/l carnitine, 100
mm Palmitic acid, 50 mg/ml gentamicin, and 1.0 mCi/ml [1-14C]-palmitate
(NEN). After 3 hr, the incubation media was transferred to new dishes and
assayed for labeled oxidation products (CO2 and acid-soluble metabolites
[ASMs]; Hulver et al., 2005). The cells were placed on ice, washed twice
with PBS, scraped into a 1.5-ml eppendorf tube in two additions of 0.30 ml




In 12-well collagen-treated plates, myotubes were washed two times in PBS
and cells were incubated at 37ºC for 30 min with 100 nM MitoTracker Green
FM (Molecular Probes). Myotubes were washed twice with PBS, and a single
in-focus optical section was acquired.
Fluorescent imaging of ROS
To analyze ROS activity in myotubes, muscle cells were incubated with the
reduced form of MitoTracker Red (MitoTracker Red CM-H2XROS; Molecular
Probes), which associates with mitochondria and becomes fluorescent after
exposure to ROS (Kukidome et al., 2006). The probe was removed by wash-
ing cells twice in PBS and cells were imaged using a confocal microscope84(Nikon Eclipse TE2000-U) with an 340 air objective. MitoTracker Red was
imaged using the HeNe 543 line and a LP 560 filter.
Statistical analysis
The significance of difference was determined by analysis of variance. In 18
Mexican subjects, age, sex, BMI, percent body fat, insulin sensitivity (M
value), fasting plasma insulin and glucose, plasma fatty acids, AMPKa1/a2
mRNA PGC1a/b mRNA, TCAD mRNA, mtTFA mRNA, citrate synthase, and
b-HAD enzyme activity were entered in stepwise regression models to
assess their contribution to the interindividual variability of mtDNA copy num-
ber, AdipoR1, and AdipoR2 mRNA. Pearson correlation coefficients were
calculated to determine the relationship between selected variables within
each group. All data are presented as means 6 SEM. p values < 0.05 were
considered statistically significant.
Supplemental data
Supplemental data include two figures and two tables and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/full/4/
1/75/DC1/.
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